Thomas C. Drees, Ph.D.
President / Chief Executive Officer

Business Summary
Sanguine Corporation (OTC Bulletin Board: SGNC), is a bio-pharmaceutical company focused on the development of PHER-O2 an oxygen-carrying synthetic substitute for human red blood cells and numerous other areas requiring oxygen perfusion.  The Company’s current product, PHER-O2 is a second generation to the previously FDA approved Fluosol DA product.  The goal is to replace the current product used for transporting living tissue, known as UW (University of Wisconsin) solution (trade name: Viaspan™). The availability of vital organs for transplant is severely limited, in part, because the systems most commonly used to preserve living tissue are based on 50-60 year old technologies and remain limited in their usefulness. As a result, organ banks do not have the true capability of storing organs for any significant length of time.  The benefit of transporting the living tissue in an Oxygenated bath is believe to significantly better the current technology available.  Once FDA approval is achieved, Sanguine believes that PHER-O2 will be used in a variety of ways, similar to Fluosol.

Sanguine Corp. (OTC BB: SGNC)

Stock Quote

Stock Charts

Company News (Historical)

Recent News: 1.  Dr. Shapiro Joins Sanguine Medical Team       2. Dr. Lakey Joins Sanguine Medical Team           Dr. Lakey Presents to Sanguine Medical Team       3. Sanguine Selects FDA Indication       4. Sanguine Files For New Patent Coverage       5. Sanguine Select Cardinal Health as Chief           Medical Consultants

Corporate Profile [Doc: 84kb]

- Quarterly Report (10QSB)
- Annual Report (10KSB)

- SEC Filings

Investor Contact
Michael Dancy
M. E. Dancy & Associates Inc.
455 East 500 South Ste.205
Salt Lake City, Utah 84111
Ph: 801-746-3570
Fax: 801-532-1765
email: medancy@sanguine-corp.com

• As a second-generation product, PHER-O2 will benefit from the limited success of its predecessor, Fluosol, developed under the management of Dr. Drees. Fluosol is the only FDA-approved synthetic red blood cell substitute, though it is not presently marketed. Management believes that its acceptance should enable Sanguine to pursue the fast track for PHER-O2 through clinical trials and the FDA approval process.
  
  
• The Company plans to capitalize on the enormous demand for its product by angioplasty. There are an estimated 700,000 cases involving angioplasty, trauma or perfusion per year in the U.S. which require or could be enhanced by PFCs or other blood substitutes. Sanguine expects to capture 25% percent of that market within three years of commercialization, generating revenues of up to $80 million annually.
  
  
• Once PHER-O2 is established as the premier product in angioplasty, Sanguine will move towards its ultimate goal: to see PHER-O2 utilized in every emergency room and ambulance across the United States - a total market potential of $7 billion.
  
  
• Sanguine is already developing a third-generation product with two profiles: OxyRich and OxyPlus. These products are designed to treat Alzheimer’s Disease and Decompression Sickness (DCS) - extending the Company’s reach into two additional - and potentially lucrative - market niches.